Cost-effectiveness of prevention program for type 2 diabetes mellitus in high risk patients in the Republic of Srpska, Bosnia and Herzegovina

被引:0
作者
Grujic-Vujmilovic, Dragana [1 ,2 ]
Veljkovic, Kristina [3 ]
Gavric, Zivana [1 ,2 ]
Popovic-Pejicic, Snjezana [4 ,5 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Social Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[2] Publ Hlth Inst Republ Srpska, Dept Social Med, Banja Luka, Republic of Srp, Bosnia & Herceg
[3] Univ Ljubljana, Fac Comp & Informat Sci, Lab Cryptog & Comp Secur, Vecna Pot 113, Ljubljana 1000, Slovenia
[4] Univ Banja Luka, Fac Med, Dept Internal Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[5] Univ Clin Ctr Republ Srpska, Banja Luka, Republic Of Srp, Bosnia & Herceg
关键词
Cost-effectiveness; Markov chain model; FINDRISC; prevention; impaired glucose tolerance; type 2 diabetes mellitus; GLUCOSE-TOLERANCE; CARDIOVASCULAR EVENTS; SCREENING-PROGRAM; UTILITY VALUES; MORTALITY; DISEASE; FOOT; LIFE; COMPLICATIONS; PROGRESSION;
D O I
10.1080/19932820.2024.2437226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Republic of Srpska (RS), as a part of the Western Balkans (WB) region, has a higher diabetes prevalence than the EU. This study aims to assess the cost-effectiveness of early treatment of high-risk patients with pre-diabetes and undiagnosed diabetes in our setting. We designed a Markov chain Monte Carlo (MCMC) model which reflects the current International Diabetes Federation (IDF) three-step plan for the prevention of T2DM in those at increased risk. The model captures the evolution of the disease in FINDRISC high-risk patients from normal glucose tolerance (NGT) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and then to T2DM and its complications. We developed two MCMC models, in order to follow the progression of the disease in high-risk cases, ie, when early treatment is undertaken or when it is not undertaken. The health costs and quality adjusted life years (QALY) were discounted at an annual rate of 3%. The key model parameters were varied in one-way and probabilistic sensitivity analysis. Early treatment resulted in increased life expectancy, postponement of the onset of diabetes and increased QALY for all patients. The discounted incremental cost-effectiveness-ratios (ICER) in NGT, IFG, IGT, and T2DM patients were -289.9, 9724.03, -1478.59 and 4084.67 <euro>. In high-risk IGT patients, ICER was the most favorable, being both a cost saving and QALY gaining, with the consistent results confirmed by the sensitivity analysis. The results recommend the acceptance of a new health policy of identifying IGT patients with the use of FINDRISC questionnaire and plasma glucose measurements; providing them with a lifestyle change program; and implementing intensive diabetes treatment, as their disease progresses. Our results are especially significant for the Western Balkan countries, since this was the first cost-effectiveness study of T2DM prevention in this region.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] The cost-effectiveness of screening for gestational diabetes mellitus in primary and secondary care in the Republic of Ireland
    Danyliv, Andriy
    Gillespie, Paddy
    O'Neill, Ciaran
    Tierney, Marie
    O'Dea, Angela
    McGuire, Brian E.
    Glynn, Liam G.
    Dunne, Fidelma P.
    [J]. DIABETOLOGIA, 2016, 59 (03) : 436 - 444
  • [22] Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
    Nguyen, Elaine
    Coleman, Craig I.
    Nair, Suresh
    Weeda, Erin R.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (02) : 210 - 215
  • [23] Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia
    AlMutairi, Manal Faleh
    Tourkmani, Ayla M.
    Alrasheedy, Alian A.
    ALHarbi, Turki J.
    Bin Rsheed, Abdulaziz M.
    ALjehani, Mohammed
    AlRuthia, Yazed
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
  • [24] The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
    Menon, Kirthi
    de Courten, Barbora
    Magliano, Dianna J.
    Ademi, Zanfina
    Liew, Danny
    Zomer, Ella
    [J]. NUTRIENTS, 2022, 14 (01)
  • [25] COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES
    Coyle, Doug
    Coyle, Kathryn
    Kenny, Glen P.
    Boule, Normand G.
    Wells, George A.
    Fortier, Michelle
    Reid, Robert D.
    Phillips, Penny
    Sigal, Ronald J.
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (03) : 228 - 234
  • [26] Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China
    Huang, Kaiyu
    Wang, Yao
    Sun, Sijia
    Zhu, Qian
    Zhou, Weifeng
    Liu, Jiatao
    Zhu, Dongchun
    Xie, Xuefeng
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [27] Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands
    de Vries, Folgerdiena M.
    Denig, Petra
    Visser, Sipke T.
    Hak, Eelko
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2014, 17 (02) : 223 - 230
  • [28] Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus
    Ward, A
    O'Brien, JA
    Salas, M
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (04) : 601 - 608
  • [29] The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan
    Ishii, Hitoshi
    Madin-Warburton, Matthew
    Strizek, Alena
    Thornton-Jones, Lucy
    Suzuki, Shuichi
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (05) : 488 - 496
  • [30] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659